creat bluematrix
 thing protein degrad primer
coverag initi buy pt
messag initi coverag buy rate pt market cap earli clinical-
stage compani focus develop first-in-class target protein degrad tpd therapi new emerg
therapeut modal great potenti view given potenti advantag tradit inhibitor respect dose potenti
side effect drug resist mechan abil address undrugg target lead candid androgen
receptor ar degrad undergo phase clinic trial treatment metastat castrat resist prostat cancer mcrpc
initi efficaci data guid second clinic candid estrogen receptor er degrad undergo
phase clinic trial breast cancer patient initi efficaci data guid
target protein degrad tpd new emerg therapeut modal great potenti view given potenti
advantag tradit inhibitor respect dose side effect drug resist abil address undrugg
target technolog matur recent year proteolysi target chimera protac among promis
tpd therapeut current develop view protein degrad naturally-occur process mediat ubiquitin-
proteasom pathway use cell multipl function elimin cellular wast misfold protein regul
protein level gene express immun antigen recognit protac similar degrad strategi seek co-opt
natur cellular machineri direct disease-driv protein interest tradit approach kinas antibody-
mediat inhibit requir target coverag molecular profil includ select bind potent function inhibit
 must bind target area kinas domain result therapeut effect contrast protac mere requir bind
interact necessarili lead function inhibit physic degrad remov target protac approach
possess sever potenti advantag tradit approach includ
abil address protein target undrugg current treatment modal accord oprea et al link
human proteom target currently-approv drug protein known small molecul inhibitor
approv drug consider protein known diseas phenotyp known small molecul inhibitor
lack small molecul inhibitor could due variou factor current inabl find function bind pocket
requir small molecul inhibit degrad latter requir bind interact bind event
need impact target function
high target select potenti confer ternari complex format protac act bind target protein one
end ligas end properli orient ternari complex ligas drive ubiquin
subsequ degrad protein interest bind alon insuffici drive degrad off-target bind
like result steric hindranc prevent ternari complex format result result ubiquin
enhanc potenc potenti due knockdown kinase-independ function normal remain target inhibit
iter mechan action scientif literatur describ sever case oncogen kinas continu drive diseas
progress via kinase-independ mechan unaffect kinas inhibit non-exhaust exampl includ mapk
pathway activ kinase-inact egfr link link link kinase-independ heterodimer braf craf link
page analyst certif import disclosur
kinase-independ transcript regul link addit protac iter mechan action wherein
molecul recycl drive target ubiquin free continu ubiuqin unlik inhibit drug spent
bound target near-complet target coverag receptor occup use antibodi approach may
import protac efficaci
signific progress made advanc protac protein degrad technolog recent year driven
consider interest small larg biopharmaceut manufactur potenti valid tremend potenti
emerg technolog first academ protac paper publish link describ bifunct peptid
recruit target protein ubiquin complex tag subsequ proteasom degrad sinc academ
scientif research develop protac technolog point clinic applic explor industri
mileston achiev includ first vivo protac link cell membrane-perm small molecul protac link
therapeutically-relev level vivo degrad link advanc spur incept wave
target protein degrad compani non-exhaust includ nurix vividion
cedilla therapeut cullgen parallel sever large-cap biotech pharma compani bayri celg
gsk novn boehring ingelheim made invest partnership agreement emerg
small platform addit large-cap compani azn novn may invest intern
effort technolog base due dilig success believ protac similar target degrad technolog
could ultim penetr estim bn ww market oncolog drug inhibitori mechan action kinas
inhibit antibodi blockad etc addit upsid indic beyond oncolog well target undrugg
current approach
initi current leader protac develop buy rate pt market
cap earli clinical-stag compani focus develop protac-bas therapi compani hold sever notabl
distinct protac field includ scientif founder chief scientif advisor professor craig crew one earli
pioneer inventor protac first target degrad compani achiev key mileston includ first vivo
oral dose protac tend larg unwieldi medicin chemistri oral bioavail perspect first
initi posit human safety/pk data two key efficaci readout approach current clinic program includ phase
androgen estrogen receptor degrad recent report posit initi safeti pk data
pt consist attribut pos-adjust pos-adjust remain
estim cash balanc year model suggest hypothet per share valuat assum favor initi efficaci
readout respect convers think stock could hypothet trade
bear-cas scenario one year result disappoint valu attribut toward earli pipelin
take conserv step-wis approach toward clinic develop may mitig near-term develop
risk view compani initi select valid target currently-approv drug ar er view reduc
risk target ultim prove clinic irrelev hand currently-us drug target could
potenti repres competit benchmark overcom would otherwis exist approach somewhat differenti
small biotech field pursu strategi screen broad librari identifi novel
linker ligas target degrad nurix target approach look select express profil
ligas diseas tissu vs healthi tissu oppos use ubiquitously-express kymera fuse tag
target poi direct degrad tag subsequ lead poi degrad elucid
proteom network wherein target poi stabil degrad influenc either directli indirectli regul poi
stabil screen coval binder determin new bind site without restrict function bind
lead clinic candid androgen receptor ar degrad phase trial mcrpc strong rational pk
data initi efficaci guid ar clinic well-valid target multipl fda-approv drug either directli
target receptor xtandi erleada nubeqa bayri pathway constitu zytiga despit
page analyst certif import disclosur
therapi mcrpc ultim becom resist ar pathway inhibitor diseas progress correspond rise prostat
specif antigen level oftentim amplif ar express ar pathway alter strongli suggest
tumor continu relianc ar-medi signal preclin data point potent ar-select profil success
degrad vivo efficaci enzalutamide-resist mous model includ patient-deriv xenograft initi human data
recent present protein degrad summit highlight posit oral pk data day half-lif earli
highly-promis safeti profil includ grade toxic mostli nausea mg human dose auc cmax
enter preclin efficaci window continu dose escal mg qd mg cohort expect read
initi efficaci data potenti either gu
estrogen receptor er degrad recent enter clinic hold promis er metastat
breast cancer mbc initi efficaci readout guid similar ar er clinic well-valid target
multipl fda-approv drug modul activ fulvestr tamoxifen conceptu er degrad alreadi valid given
fulvestr mechan action includ de-stabil er promot recognit subsequ degrad ubiquitin-
proteasom system said er level persist month fulvestr therapi agraw et al highlight potenti
improv er-target approach similar er degrad demonstr potent degrad
vivo improv preclin efficaci mous model rel fulvestr potenti synergist inhibitor initi
human data recent present protein degrad summit highlight posit oral pk data hour half-lif
initi safeti data includ treatment-rel toxic first mg qd cohort auc cmax enter
base-cas valuat scenario forecast peak bn pos-adjust ww sale
bn attribut mcrpc balanc er mbc prostat cancer repres
estim bn ww market currently-approv ar antagonist xtandi erleada nubeqa zytiga exclud given
gener statu assum po model peak market share month durat
therapi mcrpc respect could eventu see competit emerg mcrpc
therapi psma-target radiopharmaceut parp inhibitor brca tumor recent approv increas util
ar inhibitor non-metastat metastat cnpc like tailwind system therapi see prostat
cancer kol takeaway think er mbc repres potenti bn ww market major account
inhibitor given brand statu balanc gener endocrin therapi assum
po model peak share month durat therapi endocrine-pretr refractori
mbc patient respect er competit landscap could also potenti shift next-gener select er
undergo develop though monotherapi efficaci data thu far modest
protac neurolog indic addit partnership rest pipelin repres potenti sourc upsid
current valuat addit clinical-stag asset compani also disclos pursu next-
gener ar degrad lead optim well explor degrad current discoveri stage beyond oncolog
develop neurolog protac asset demonstr select potent bind anti-tau protac oligomer
patholog tau normal monomer form along vivo penetr blood-brain barrier parenter administr
offici disclos pend patent potenti provid insight toward futur protac target includ clinically-
valid target egfr raf well target underli biolog rational on-going partnership
bayri gener involv early-stag develop target select partner would exclus
ww option in-licens develop exchang potenti development regulatori sale mileston royalti net
sale furthermor bayri joint ventur oerthbio focu potenti use protac technolog
agricultur
page analyst certif import disclosur
thing biotechnolog
page analyst certif import disclosur
tabl content
page analyst certif import disclosur
page analyst certif import disclosur
page analyst certif import disclosur
takeaway target protein degrad tpd new potenti
target protein degrad tpd new emerg therapeut modal
tpd approach seek hijack natur ubiquitin-proteasom machineri within cell select potent degrad target
goal modul level clinically-relev protein
modal conceptu valid currently-approv immunomodulatori imid imid revlimid celg
er antagonist fulvestr faslodex azn trigger protein degrad part mechan action
protac proteolysi target chimera among promis tpd therapeut current
develop view
protac heterobifunct small molecul recruit ligas target protein interest poi degrad
degrad target rather tradit inhibit also elimin secondari activ kinase-independ function
larg grow bodi evid demonstr protac potenc select tradit modal kinas inhibit
potenti address tradit undrugg target inaccess antibodi lack small molecul bind pocket
attract consider recent attent scientist investor big pharma
success protac could potenti penetr bn ww market cancer protein inhibitor addit
indic neurolog previous undrugg target repres potenti upsid
grow interest larg compani field partnership bayri celg gsk
boehring ingelheim intern effort azn novn base analysi
advanc protac tpd platform among small biotech nurix kymera cedilla cullgen krono
hinova etc pursu target degrad strategi view
page analyst certif import disclosur
takeaway initi coverag buy rate
pioneer therapeut tpd applic
pioneer proteolyt target chimera protac novel class therapeut within field tpd scientif
team first overcom histor barrier protac membran permeabl oral bioavail etc
compani scientif founder first achiev multipl mileston includ first vivo oral dose complic
molecul medicin chemistri oral bioavail perspect first-in-human clinic trial
arvn step-wis approach overal pipelin strategi mitig potenti develop risk view
initi highlight drug-lik properti oral dose non-tradit small molecul current pursu valid target
androgen receptor ar estrogen receptor er order clinic valid protac platform approach prior move
patent applic suggest valid protac target may includ egfr raf
potent select first-in-class potenti best-in-class androgen receptor ar degrad
could potenti penetr mcrpc market current domin ar antagonist xtandi
erleada nubeqa bayri repres estim bn ww market
degrad ar potenti address mcrpc obtain resist ar inhibitor xtandi remain
depend ar pathway signal potenti path single-arm acceler approv popul
on-going phase patient enter therapeut window base preclin data experienc grade toxic
potent select first-in-class potenti best-in-class estrogen receptor er degrad
er breast cancer repres estim bn ww revenu opportun bn attribut inhibitor
er degrad valid concept fulvestr faslodex azn currently-approv select estrogen receptor degrad
serd class molecul see addit clinic develop next-gen molecul
on-going phase clean safeti profil observ toxic thu far lowest dose complet dose escal lead
phase ib dose expans combin inhibitor
page analyst certif import disclosur
target protein degrad tpd therapeut categori
complement current biotechnolog oncolog coverag
antibodi select deliv chemotherapeut
payload cancer cell
har patient immun system target cancer
small molecul inhibitor shut aberr
kinas activ cancer-caus protein
small molecul select trigger prevent
degrad target protein
page analyst certif import disclosur
rate buy earli clinical-stag biotech
compani platform focus proteolysi target
chimera protac novel therapeut modal use target
protein degrad tpd overcom limit tradit
approach kinas inhibit compani pioneer
whose scientif founder earli discover protac
first gener posit initi proof-of-concept safeti pk
human lead asset androgen estrogen
receptor protac respect success think
protac modal high potenti disrupt standard-of-car
paradigm across mani therapeut area pt
current share price consensu
viabil protac technolog yet clinically-
valid poc efficaci human
lead small biotech tpd invest
field big pharma may increas competit
market potenti clinic bar
competit categori
initi clinic efficaci ar degrad
initi clinic efficaci er degrad
chart slide overal market perform
page analyst certif import disclosur
clinical-stag biotech pioneer field target protein degrad tpd treatment cancer therapeut
indic pipelin focus novel class molecul name protac recruit cell natur ubiquin proteasom machineri tag
subsequ induc degrad disease-caus protein protac novel technolog potenti address current unmet need across oncolog
 neurolog overcom limit tradit modal kinas inhibit mab-bas therapeut
pipelin consist clinic candid select androgen ar estrogen receptor er degrad current earli
clinic trial posit initi poc safeti pharmacokinet data addit target indic protac platform well posit
newsflow collabor revenu bayri partnership joint ventur could gener long-term upsid
page analyst certif import disclosur
bull first-in-class pioneer highli
scientif founder among first technolog
continu spearhead academ protac research
compani first mani mileston protac
includ first oral vivo dose first-in-human trial
potenti first- best-in-class therapeut given
promis poc head start potenti competitor
conserv clinic develop plan pursuit
bear earli unproven technolog
potenti high degre develop risk
high degre develop risk compani ultim
current lack human proof-of-concept efficaci data
first-in-class rapidli increas interest
think concept target protein degrad
robust scientif rational emerg clinic poc tpd
undergon year research pioneer
mani key mileston develop technolog scientist
also establish tpd import mechan
revlimid celg faslodex azn
although lead small biotech tpd big pharma
could potenti surpris multipl biotech develop
tpd platform remain larg discovery/preclin
wherea first-in-human data pharma quiet
develop plan invest tpd seen recent
public hire tpd pioneer senior role
compani clinic strategi conserv mitig
develop risk view arvn first clinic target ar
er clinically-valid said establish target
could set higher competit bar commerci success
key year data on-going clinic program
broader pipelin potenti sourc upsid first-in-class
ar er degrad initi efficaci readout
respect program neurolog agricultur
repres long-term upsid view
revenu forecast street consensu
averag pt current share price
peer estim
 bull/bear case month
page analyst certif import disclosur
per dcf
bn mcap wacc termin growth line
assumpt biotech compani without clinic
proof concept
po prostat cancer
po breast cancer
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
valu pipelin agent platform
posit efficaci readout
clean safeti po increas
posit efficaci readout
clean safeti po increas
neg readout
remov valuat
compani trade cash valu
page analyst certif import disclosur
page analyst certif import disclosur
page analyst certif import disclosur
incom statement sales- collabor royalties- total cogs- total cost oper incom interest interest incom incom incom tax- net incom net incom loss attribut dilut ep per share outstand bs cf sourc guggenheim secur llc estim sec file select manag leadership team member
yale univers professor earli pioneer field target protein degrad spearhead earli protac work
establish academ proof-of-concept small molecul membran permeabl protac first vivo protac etc
all-in crew lab invent includ -yal licens agreement professor crew restrict
conduct sponsor research collabor similar arrang target protein degrad for-profit
previous cso presid svp specialti discoveri evolut chair target
portfolio committe chair site evolut steer committe involv develop opdivo yervoy
previous cfo cfo crgn director control life scienc corpor
previous svp head clin research tsro vice-president global oncolog develop
clinic develop lead yervoy zejula tsro gsk previous work atyp antipsychot abilifi
previous earli develop lead oncolog sr dir translat oncolog
vice-president neurosci platform biolog angela cacac ph
previous vice-president biolog director genet defin diseas assoc dir neurodegener
guggenheim secur llc analysi sec file corpor slide
page analyst certif import disclosur
technolog overview
page analyst certif import disclosur
ubiquitin-proteasom system primarili respons
regul protein level cell via protein degrad
overview ubiquitin-proteasom protein degrad pathway
protein becom degrad target degrad normal occur reason
elimin mis-fold protein link neg feedback regul
subset ubiquitin ligas naturally-occur ligas identifi
date recogn bind target protein begin degrad process
ligas recruit ubiquitin-conjug enzym ubiquitin
shown ubiquitin-activ enzym activ transfer ubiquitin
ubiquitin repeat target protein polyubiquitin
recogn proteasom degrad constitu peptid
nobel prize chemistri
award discoveri ubiquitin-
page analyst certif import disclosur
ups-medi protein degrad natur role includ protein
qualiti control gene regul immun recognit antigen
qualiti control protein synthesi
promot intracellular protein agglutin recogn
misfold protein may expos hydrophob residu
ubiquin subsequ degrad amm link
regul gene express
select degrad transcript factor lack thereof modul
antigen lead antigen peptid bind mhc class-i molecul
ups-medi degrad intracellular foreign protein viral
present cytotox t-cell sijt link
page analyst certif import disclosur
target protein degrad tpd therapi seek co-opt
select modul level disease-caus protein
therapeut tpd remov disease-caus protein
increas level disease-suppress protein
currently-approv fulvestr immunomodulatori
protein degrad part mechan action
hine link scaveng ligas
suppress degrad tumor suppressor
potenti synerg anti-neoplast drug
page analyst certif import disclosur
proteolysi target chimera protac advanc
target degrad therapi develop
 recruit ligas
 target protein
bind target protein
degrad
protac mechan action overview
key target ubiquin
page analyst certif import disclosur
target unlik tki mab efficaci
target protein degrad tpd therapi reus multipl therapeut target
kinas inhibitor inher limit
drug-to-target coverag ratio
monoclon igg antibodi similarli
limit receptor occup fashion
page analyst certif import disclosur
potenti protac advantag possibl design protac
on-target potenc select
potenti potenc tki made protac
rel potenc tki inhibit vs protac degrad
protac use respect tki protein-bind domain
select confer need properli orient target
protein ligas ternari complex format
see burslem exampl use
page analyst certif import disclosur
independ function target protein scaffold role
inact kinas drive surviv pathway
tpd potenti block tki bypass pathway
activ compensatori mechan
degrad physic remov disease-
drive kinas could address bypass pathway
egfr kinase-independ function drive cancer growth weihua weihua downregul egfr either
degrad gene knockdown induc cancer cell death inhibit insuffici katreddi multipl studi
demonstr egfr without kinas still activ mapk pathway campos-gonzalez selva ewald other
suggest inact egfr could activ rtk without tyrosin phosphoryl deb
kinase-independ function act transcript regul kollmann promot tumor angiogenesi
braf heterodimer craf braf kinase-independ manner trigger downstream mapk signal hale
fak numer kinase-independ scaffold function canc beraud fan remain un-address kinas
inhibit suscept protac-medi degrad cromm
page analyst certif import disclosur
potenti self-synerg depend target engag
protac hine link
overview mechan action synergi
member bromodomain extratermin
bet famili act transcript regul
tumor tend reli c-myc overexpress extens
depend c-myc one target gene
mous doubl minut homolog
ligas act neg regul tumor suppressor
dual synergist mechan
target degrad subsequ result
down-regul c-myc oncogen
scaveng free inhibit function
down-regul tumor suppressor
page analyst certif import disclosur
diseas phenotyp lack small molecul drug
proteom target develop level
tclin protein target least one approv drug
accord oprea et al exampl includ braf
tchem protein target approv drug
specif target protein known small molecul
capabl bind exampl includ etc
potenti target
degrad improv
protein target confirm diseas
potenti address
diseas phenotyp
tdark protein meet tclin tchem criteria
therapeut typic cite human
proteom undrugg convent method
page analyst certif import disclosur
protac-medi degrad wide varieti target
demonstr scientif public
repres list tpd target recruit ligas
page analyst certif import disclosur
potenti consider protac
page analyst certif import disclosur
oral formul protac may somewhat complic physical-
chemic properti push histor boundari oral drug
protac may push boundari oral bioavail
protac literatur tend
push boundari
benet within sampl approv drug oral violat lipinski rule vs non-or
howev schultz highlight timelin new drug push boundari oral drug-lik properti doak doak
degoey poongavanam review oral drug beyond rule five
major vivo protac dose via inject public first describ oral vivo protac via
er degrad separ group sun demonstr oral vivo degrad
furthermor demonstr first-in-human oral dose protein degrad summit
page analyst certif import disclosur
protac may self-inhibitori high concentr hook effect
could implic dose pk optim
unlik inhibit equilibrium protac mechan exist non-coop equilibrium
protac degrad kinet model protein interest poi
system self-inhibit high concentr
empir demonstr protac
auto-inhibit degrad high protac
concentr protac scaveng free ligas poi
prevent format protein degrad complex
data bondeson link
self-inhibit high
page analyst certif import disclosur
screenabl potenti protac librari may key identifi
optim compound given therapeut area diseas state
specif protac molecul
specif diseas set
potenti issu
present healthi
presenc diseas
healthi tissu
compani unlik design protac space
given potenti issu potenc view
ligas presenc diseas vs tissu
warhead bind target protein interest poi usual
consider warhead design may includ baselin
impact orient target protein target ligas
linker length exampl impact protac degrad
ligas encod cell
 crbn vhl use protac choic
ligas may impact potenc link
larg number possibl protac given interdepend among
domain high possibl structur compani
select ligas distribut may impact protac
 nurix messag character addit ligas
kymera messag select target select degrad
describ potenti method expand protac toolbox includ novel
ligas differ tissu express profil recruit protac
page analyst certif import disclosur
research identifi potenti method protac
public zhang link
alter key
scaffold protein part
mutat gene lead non-funct protein
introduc exogen re-sensit cell
loss crbn express
resist imid zhu link
interestingli alter observ
equival crbn ligas
genet delet crbn primari caus myeloma
crbn express predict biomark multipl
myeloma patient receiv imid broyl link bila
observ vitro resist
due ligas alter
rather target protein
line zhang et al hypothes defici dna repair
 atm mutat could contribut resist
manag cite investor confer
observ mechan resist down-regul
specif ligas use protac contrast abbv public
page analyst certif import disclosur
overview tpd market opportun
page analyst certif import disclosur
success tpd may penetr bn ww market cancer
protein inhibitor addit potenti upsid undrugg target
estim includ addit
target could potenti becom
guggenheim secur llc analysi evaluatepharma sale ww consensu estim oncolog therapeut exampl inhibitor parp inhibitor hdac inhibitor proteasom inhibitor exampl oncolog
page analyst certif import disclosur
scientif interest progress protac technolog evolv
stage clinic applic may explor industri
number protac articl display pubm
pubm search protac manual filter result
valid protac
univers ky
present sabc
protac degrad
vivo tumor regress
crpc protac
nm concentr vivo data
winter link degrad
nm concentr vivo data
page analyst certif import disclosur
target protein degrad compani attract consider
level invest non-dilut financ partnership
privat invest financ timelin select compani
recent acceler pace equiti
 up-front cash invest
target protein degrad
page analyst certif import disclosur
spearhead first-in-human target protein degrad
biotech compani follow behind
page analyst certif import disclosur
sever larg biopharmaceut compani activ pursu
select exampl target protein degrad partnership
partnership typic includ license access protein degrad platform research target discoveri
exchang equiti invest mileston payment royalti licensor
page analyst certif import disclosur
recent public key hire suggest increas intern
invest protac compani
partnership mission therapeut focus deubiquityl enzym inhibitor
applic alzheim parkinson diseas
select public protac
zhang link character protac resist via chang ligas complex
hire raymond deshai phd hire svp discoveri research current
svp global research previous caltech professor lead investig earli protac work
select public protac
wurz link imid-bas protac degrad potenti applic r/r aml
select azn public protac
edmonson link review highlight progress potenti challeng protac
mccoull link degrad induc phenotyp respons dlbcl
hire jame bradner md hire presid novarti institut biomed research
previous medic oncologist dana-farb co-found
select novn public protac
nowak link interprotein contact confer protac select
nabet link dtag system tag specif protein interest degrad
merck partnership expir
 on-going led jason imbriglio
page analyst certif import disclosur
ultim believ tpd broad enough therapeut categori
multipl compani differenti strategi succeed
step-wis approach clinic develop given spearhead new technolog
recent demonstr initi data highlight oral drug-lik properti human
initi pursuit well-valid clinic target androgen receptor estrogen receptor prior
move toward difficult valid target undrugg target
pursu complementari platform modul either activ ligas
broad screen librari identifi novel linker ligas target degrad
target approach wherein compani pursu indic preferenti ligas
local oppos ubiquit express crbn vhl etc
develop target biolog rational select drug
enter clinic
daedalu platform incorpor chemistri structur biolog optim target degrad
atag technolog platform gener protein tag fuse target protein interest
mark subsequ degrad molecul direct tag
identifi network protein interact determin stabil protein-of-interest
direct small molecul degrad bind protein interest destabil protein allow
cellular machineri proceed degrad
indirect small molecul bind regul protein-of-interest stabil
screen librari small molecul coval binder target cystein proteom
gener pocketbind could inhibit activ trigger target degrad target
page analyst certif import disclosur
ar degrad castration-
page analyst certif import disclosur
ar pathway antagonist act differ point ar signal
suppress prostat cancer emerg resist mechan
overview androgen receptor signal
cholesterol convert pregnenolon
 progesteron
synthes via testosteron
castrat downregul testicular
abirateron inhibitor
ligand-independ activ ar
up-regul
ar-depend independ
pathway see
extracellular testosteron transport
cell via shbg convert
dihydrotestosteron
ar bind dissoci
heat shock protein hsp shown
bayri non-steroid molecul
competit bind ar
inhibit bind
ar amplif overexpress
ar mutat bind pocket
pocket constitut activ
glucocorticoid receptor gr
phenotyp switch neuroendocrin
ar-dht transloc nucleu
dimer promot express
gene necessari prostat cell growth
ar inhibitor inhibit transloc
ar nucleu well ar
page analyst certif import disclosur
nccn guidelin highlight current standard care consist
androgen depriv ar pathway antagon docetaxel
kol check indic major
mcrpc patient receiv least
one ar pathway inhibitor docetaxel
page analyst certif import disclosur
ar antagonist mainstay prostat cancer brand
currently-approv product estim reach bn ww
ar pathway antagonist standard care
ar antagonist forecast compound-annual-growth-rate
product develop phase i/ii product psma t-
zytiga gener abirateron forecast includ due
zytiga loss exclus well mechan action
inhibit androgen synthesi via rather ar inhibitor
page analyst certif import disclosur
